Contents lists available at ScienceDirect

Cancer Letters

journal homepage: www.elsevier.com/locate/canlet

Mini-review

Nitric oxide in cancer metastasis

CrossMark

Huiwen Cheng [a,c], Lei Wang [a,c], Molly Mollica [a,c], Anthony T. Re [b], Shiyong Wu [a,c,*,1], Li Zuo [b,*,1]

[a] Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701, USA
[b] School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH 43210, USA
[c] Edison Biotechnology Institute, Konneker Research Center, Ohio University, Athens, OH 45701, USA

ARTICLE INFO

ABSTRACT

Cancer metastasis is the spread and growth of tumor cells from the original neoplasm to further organs. This review analyzes the role of nitric oxide (NO·), a signaling molecule, in the regulation of cancer formation, progression, and metastasis. The action of NO· on cancer relies on multiple factors including cell type, metastasis stage, and organs involved. Various chemotherapy drugs cause cells to release NO·, which in turn induces cytotoxic death of breast, liver, and skin tumors. However, NO· has also been clinically connected to a poor cancer prognosis because of its role in angiogenesis and intravasation. This supports the claim that NO· can be characterized as both pro-metastatic and anti-metastatic, depending on specific factors. The inhibition of cell proliferation and anti-apoptosis pathways by NO· donors has been proposed as a novel therapy to various cancers. Studies suggest that NO·-releasing non-steroidal anti-inflammatory drugs act on cancer cells in several ways that may make them ideal for cancer therapy. This review summarizes the biological significance of NO· in each step of cancer metastasis, its controversial effects for cancer progression, and its therapeutic potential.

© 2014 Elsevier Ireland Ltd. All rights reserved.

Introduction

Cancer metastasis is the spread and growth of tumor cells through angiogenesis, invasion, colonization, and ultimately proliferation from the original neoplasm to other organs [1], which can be extremely difficult to treat and therefore often lead to death (Fig. 1) [2,3]. Nitric oxide (NO·) is a signaling molecule that plays various roles pathologically and physiologically [4]. In the last

two decades, the function of NO· in the regulation of cancer formation, progression and metastasis has been extensively investigated [5,6]. Activation of nitric oxide synthase (NOS) and elevation of NO· have exhibited an antitumor nature [7–9]; however, NO· may also promote cancer formation and progression [10–12]. Therefore the effect of NO· on metastasis cannot be easily classified as "pro-metastasis" or "anti-metastasis" as it may rely on other factors such as the cell type [13], dosage [14,15], organs involved [13], or even which step of metastasis NO· influences. This review will summarize the current knowledge on the influence of NO· in tumor progression and metastasis. The potential therapeutic applications of NO· in cancer treatment will also be discussed.

NO· was first discovered as a vasodilator in the cardiovascular system [16]. Recently, NO· has been found to have a pleiotropic effect on platelet aggregation [17], immune response [18], and signaling pathways critical to tumor progression [19], all of which affect tumor cell metastasis [17,20,21]. NO· is synthesized from L-Arginine and oxygen by a family of enzymes termed nitric oxide synthases (NOSs). The three isoforms of NOS include neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3). Because nNOS and eNOS undergo constitutive expression, they have also been named constitutive NOS [22]. These isoforms are significant because NOS expression in tumors differ from case to case, exhibiting their heterogeneous characteristics in cancer metastasis [23].

Fig. 1. This schematic demonstrates the typical progression of tumor cell metastasis. Abbreviations: extracellular matrix (ECM), matrix metalloproteinase (MMP).

NO$^\cdot$ has a paradoxical role in certain malignancies and prognoses. A recent clinical study showed that patients with iNOS-positive tumors had a significantly lower disease-specific survival rate than those with iNOS-negative tumors in various stages of colorectal cancer, suggesting iNOS overexpression is related to increased disease-specific fatality [24]. Analysis of the relationship between angiogenesis and iNOS in primary gallbladder carcinomas has shown that the degree of malignancy is significantly affiliated with the expression level of iNOS [25]. In breast cancer, NO$^\cdot$ is shown to decrease aggressiveness of breast tumor cells by inhibiting cell motility and reinforcing cell adhesion, ultimately hindering the cell's metastatic characteristics [26]. While NO$^\cdot$ has been clinically connected to a poor cancer prognosis, not all the effects of NO$^\cdot$ are clear and may be impacted by dose or organs involved.

Mice transfected with an iNOS-negative retrovirus led to the formation of multiple lung metastases and aggressive, subcutaneous tumors. However, cells infected with iNOS-positive retrovirus formed few lung metastases and slowly progressing tumors [27]. In addition, when the metastatic cells of murine M5076 were transfected with functional iNOS genes, the established hepatic lesions and tumorigenesis regressed [8]. In syngeneic C57BL/6 mice, lower levels of iNOS produced tumors in the pancreas that metastasized to the liver and formed ascites. However, higher levels of iNOS expression did not result in liver metastases or ascites [28]. These results suggest that NO$^\cdot$ may drastically impede or even eliminate metastatic progression. Yet, the effect of NO$^\cdot$ on tumor metastasis appears to be organ-specific. A study exploring the effects of heme oxygenase and NO$^\cdot$ on pulmonary or liver metastasis of colon cancer in mice found that the mice receiving NG-nitro-L-arginine methyl ester, an inhibitor of eNOS, had an increased number of tumor cells 24 h later. Those same mice had an increased number of pulmonary metastases 18 days later, but possessed a similar number of liver metastases as untreated mice [13]. Since eNOS showed anti-metastatic effects on pulmonary metastases but no effect on liver metastases, these results suggest that rather than NO$^\cdot$ being correctly labeled "pro-metastasis" or "anti-metastasis," the setting and organs involved have a great effect on the manifestation of NO$^\cdot$ [13].

During *in vitro* and *in vivo* conditions, NO$^\cdot$ exercises its antitumor nature by inducing cytotoxicity and apoptosis, effectively influencing tumor metastasis [7,29–31]. Galectin-3 is a carbohydrate-binding protein that is important for cell–cell and cell-matrix interactions and cancer metastasis [32]. NO$^\cdot$ is involved in the mechanism by which galectin-3 enhances metastasis. In human breast carcinoma (BT549) cells, galectin-3 improves metastatic potential and protects tumor cells from death through the iNOS cytotoxicity pathway [33,34]. Paclitaxel, an antineoplastic drug that introduces cytotoxicity against cancer cells, was shown to accomplish its effect through stimulation of NO$^\cdot$ production in human liver cancer cells HepG2 [35]. In addition, two natural

and structurally similar polyphenols, trans-pterostilbene (t-PTER) and quercetin (QUER) were administered to mice and found to impede the metastasis of B16F10 melanoma cells by causing NO$^\cdot$ to be released from the vascular endothelium, resulting in the cytotoxicity and death of B16F10 cells (Fig. 2) [36].

In addition to anti-cancer effects through cytotoxicity, there is sufficient evidence suggesting anti-cancer effects of NO$^\cdot$ through apoptosis [14,37]. Many cancers show resistance to apoptosis by suppressing the genes that promote apoptosis. This resistance largely contributes to poor prognosis by affecting tissue homeostasis and causing failure of treatments [38,39]. Through the use of a series of adenoviral vectors that expressed different levels of iNOS activity, Xie et al. reported that although NO$^\cdot$ has some pro-tumor activity such as mediated gene transfer and up-regulated angiogenetic molecules, the antitumor actions including loss of malignancy due to apoptosis outweigh the pro-tumor factors and result in an overall deregulation of malignancy [14]. These dichotomous effects on cancer progression arise from NO$^\cdot$ regulations on specific signaling pathways [40]. Successful cancer metastasis consists of several complex, consecutive, and particular steps [1]. Numerous evidence suggests that NO$^\cdot$ plays important roles in nearly all steps of cancer metastasis [6].

Invasion

Invasion consists of alteration in tumor cell adhesion to the extracellular matrix (ECM), proteolytic degradation of encompassing tissue, and migration of tumor cells (Fig. 1) [1,41–43]. During invasion, the matrix metalloproteinase (MMP) family is responsible for the essential degradation of the ECM [44,45] while integrins likely assist in locomotion: the forward migration synchronized by operations of actin cytoskeleton filaments [46].

MMPs exist at a high level in malignant cells, but are expressed at basic levels in normal cells. NO$^\cdot$ was found to modulate MMP expression and therefore affects tumor cell invasion [47–50]. The invasion-inhibiting effects of NO$^\cdot$ on the 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced MMP-9 expression was examined in human breast cancer cell line MCF-7. It was observed that a supplement of NO$^\cdot$ donors lead to a decrease of MMP-9 mRNA levels and reduction of MMP-9 translations. A 0.67 kb fragment from the 5′-promoter region of the MMP-9 gene is primarily responsible for the inhibition of MMP-9 by NO$^\cdot$ [50]. Furthermore, the TPA-triggered protein kinase C (PKC) activity was significantly inhibited by NO$^\cdot$ in MCF-7 cells, indicating that NO$^\cdot$ attenuates TPA-induced MMP-9 expression mediated by the PKC pathway [50] and therefore avoids invasion. Conversely, an examination of human melanoma cell line C32TG found NO$^\cdot$ enhanced MMP-1, -3, -10 and -13 expression transcriptionally via the mitogen-activated protein kinase (MAPK) (ERK/p38) pathway [49], thereby assisting

Fig. 2. This schematic demonstrates the multitude of mechanisms through which nitric oxide increases or decreases the activation of and prevalence of cancer metastasis. Abbreviations: extracellular matrix (ECM), endothelial leukocyte adhesion molecule 1 (ELAM-1), guanylyl cyclase (GC), human umbilical vascular endothelial cells (HUVECs), Cytokine interleukin-33 (IL-33), mitogen-activated protein kinase (MAPK), matrix metalloproteinase (MMP), Nitric oxide (NO·), protein kinase C (PKC), quercetin (QUER), trans-pterostilbene (t-PTER).

tumor metastasis (Fig. 2). This difference also suggests a potential cell-type dependent effect of NO· on MMP expression and invasion.

Integrins are a family of cell surface proteins that mediate cell-to-cell and cell-to-matrix attachment, control the adherence of tumor cells to and in the ECM, and likely aid in locomotion, thereby impacting tumor cell invasion [46,51–53]. NO· specifically inhibits α2β1 integrin-mediated platelet adhesion to immobilized collagen [52]. Activation of integrin α9β1 enhances cell migration through the induction of iNOS expression triggering cGMP generation via guanylyl cyclase (GC) [46]. NO· from human umbilical vascular endothelial cells (HUVECs) promote cell adhesion of human fibrosarcoma HT1080 to HUVEC monolayer by enhancing endothelial leukocyte adhesion molecule 1 (ELAM-1) expression on HUVECs. This further increases tumor cell invasion through the HUVEC monolayer (Fig. 2) [54]. Therefore, in addition to evidence of pro- and anti-invasion effects, NO· reduces adhesion and promotes migration, and therefore invasion, through inhibition of integrin expression [46,51–53].

Angiogenesis

Angiogenesis is the growth of new blood vessels from the original vascular bed and is an essential step in tumor progression and metastasis [55]. An analysis using samples from normal liver tissue and hepatocellular carcinoma patients demonstrates that iNOS positively modulates MMP-9 expression, facilitating tumor cell angiogenesis, invasion, and metastasis [56]. Compared to normal tissue, tumor specimens from head and neck cancer showed higher NOS activity, which is associated with a higher level of angiogenesis. When the production of NO· is obstructed, tumor angiogenesis is suppressed [57,58]. Cytokine interleukin-33 (IL-33), a regulator of vasculature, was also shown to promote proliferation, migration, angiogenesis and vascular permeability by stimulating endothelial NO· generation through the ST2/TRAF6-Akt-eNOS signaling pathway [59]. In addition, the reduction of NO· formation achieved by knockdown of eNOS using siRNA markedly decreased endothelial cells

migration in shear stress, which typically stimulates angiogenesis through a NO-mediated pathway. However, a supplement of external NO· donors led to a 2-fold recovery in angiogenesis (Fig. 2) [60].

Intravasation

Although less documented, evidence suggests that NO· is also involved in the process of intravasation, which occurs when tumor cells invade the blood vessels. Leukocytes are circulated throughout the body to defend against tumor cell invasion in blood vessels. Significant to intravasation, the rolling and adhesion, and therefore effectiveness, of leukocytes on the endothelium in tumor vessels is largely reduced in an NO· and intercellular adhesion molecule-1 (ICAM-1) dependent manner. In addition, as shown in Fig. 2, inhibition of NO· partially reverses the lack of adhesion of leukocytes in tumor microvessels, suggesting that NO· has pro-intravasative effects [61].

Extravasation and colonization

During extravasation and colonization, the tumor cells prompt endothelial retraction that leads to the adhesion of tumor cells to the subendothelial ECM and the reformation of the capillary (Fig. 1). When a tumor cell attaches to coagulation factors such as fibrin, thrombin, or fibrinogen, an embolus is created and, with the assistance of E- and P-selectins, it causes cell arrest in the capillary beds. NO· has been shown to decrease the expression of E-selectins through inactivation of NF-kappaB, thereby resulting in an anti-metastatic outcome [62]. However, a selective iNOS inhibitor (e.g., 1400 W dihydrochloride) attenuated the mRNA transcription of E-selectins in pulmonary artery endothelial cells [63].

Lymphatic metastasis

Lymphatic metastasis is a common and crucial factor for cancer pathogenesis [64]. The lymph nodes are the primary metastasis

location for most malignancies and they are a critical determinant in the prognosis of the patient. Two important factors in promoting lymphatic metastasis are vascular endothelial growth factor-C (VEGF-C), by which lymphangiogenesis is stimulated [65], and the CXC chemokine receptor 4 (CXCR4), which is shown to be a contributor to lymph node metastasis [66]. With the treatment of the NO· donor DETA NONOate, the production of VEGF-C increases. Furthermore, when treated with an NO·-synthesis impeder N-nitro-L-arginine, VEGF-C production is halted [67]. In addition to VEGF-C, NO· stimulates cytoplasmic CXCR4 expression and therefore may also be characterized as pro-metastatic due to its possible aiding of lymphatic metastasis in human breast carcinoma cells [66].

Hypoxia evasion

Hypoxia occurs when the entire or part of the body is deprived of oxygen [68]. When this occurs in a tumor, it may lead to further tumor metastasis due to therapy resistance and accelerated invasion, and is not characterized with a promising prognosis for patients with many types of cancer [69,70].

NO· evokes hypoxia-inducible factor-1 (HIF-1), a transcription factor that enhances many hypoxia-inducible genes, via PI3k/Akt pathway [71,72]. As mentioned previously, an open-label 24-month clinical trial shows that NO· annihilates prostate cancer metastasis by weakening hypoxia-induced progression [73]. In B16F10 cells, the presence of low-concentration NO·-mimetics caused an inhibition in hypoxia-induced lung nodule formation. When NOS was repressed, it caused lung nodule formation in a hypoxia-similar fashion. This regulatory effect of NO· involves a cGMP-dependent pathway [70].

The effect of NO· also relies on the presence of additional substances. Together, expression of iNOS and cyclooxygenase (COX-2) has been found to be responsible for enhanced vascular invasion, lymphatic metastasis and angiogenesis in various cancers. Although we cannot define both iNOS and COX-2 as exclu-

sively pro- or anti-metastatic in gastric adenocarcinoma patients, the combined production of NO· and prostaglandins via iNOS and COX-2 expression can be associated with cancer progression, tumor angiogenesis, and a graver prognosis [74]. Besides COX-2, the Src kinase family, a key regulator of cell invasiveness, is shown to phosphorylate iNOS Tyr (1055) and stabilize iNOS half-life, thereby producing a constantly large amount of NO· to regulate tumor metastasis [75].

Nitric oxide therapy

It is clear that NO· plays a significant role in tumor progression and metastasis. The bimodal effects of NO· have been established through studies focusing on variables affecting NO· impact. These factors include duration of NO· exposure, cellular microenvironment, NO· flux, tumor cell cycle stage, as well as prevalence of oxidizing and reducing agents [76]. Since the influence of NO· is also dependent on the concentration, it has been shown that angiogenesis, proliferation and metastasis can normally be stimulated by lower levels of NO· (<100 nM). However, higher concentrations of NO· (>400–500 nM) do not facilitate tumor progression but instead promote cytotoxicity and cell apoptosis [40,76]. Accordingly, the inhibition of cell survival and anti-apoptosis pathways by NO· donors has been proposed as a novel therapy to various cancers [4,77]. Most of the research has been in the area of nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO·-NSAIDs), which has been particularly promising. In many cases, NO· appears to exhibit both combinatory and enhancing effects on pre-existing anticancer effects of the parent NSAIDs. Several studies have found a link between NSAIDs use and decreased risk of colorectal cancer [78–80], suggesting a possible chemopreventive role. NO·-NSAIDs have been shown to be more effective in the inhibition of cancer cell growth and metastasis than the parent drug alone [77,81].

Evidence suggests NO·-NSAIDs act on cancer cells in several ways. First, they inhibit cell proliferation by decreasing expression of proliferating cell nuclear antigen (PCNA) [82]. PCNA is a protein


Fig. 3. This flowchart highlights the increased effectiveness of NSAIDs contrasted to NO·-NSAIDs in blocking cancer development. Abbreviations: nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO·-NSAIDs), proliferating cell nuclear antigen (PCNA).

that acts as a processivity factor for DNA polymerase delta in eukaryotic cells. It plays an important role in DNA synthesis, and as such, decreased PCNA expression leads to decreased DNA synthesis and reduced cell proliferation. However, this decrease in PCNA expression has not been shown to correspond linearly to the decrease in cell proliferation, so it appears that other factors are involved [82]. NO·-aspirin exhibits greater pro-apoptotic effects than aspirin itself. Interestingly, NO·-aspirin also induces a large population of "atypical" cells [82,83]. These "atypical" cells exhibit diminished or no DNA while retaining their basic cellular structure. NO·-NSAIDs also appear to block cell cycle transitions from G_0–G_1 to S, further inhibiting growth (Fig. 3) [82].

Accordingly, NO·-NSAIDs may likely augment cellular pathways favorable to apoptosis and diminish metastasis in certain cell types. For example, the anti-cancer effects of NO·-NSAIDs may not help reduce metastasis in hepatocytes, endothelial cells, B-cell lymphomas, and other cell lines, where NO· has been shown to obstruct pro-apoptotic mechanisms [84–86]. However, other tumor cells such as breast carcinomas have been shown to undergo apoptosis following prolonged exposure to elevated NO· concentrations (1 mM) [40]. In colon adenocarcinomas, NO·-NSAIDs repress tumor proliferation through epigenetic contributions such as DNA methylation and histone modifications [76,82].

Another study found that nitric oxide-donating prodrugs significantly enhanced the efficacy of the chemotherapy drug fludarabine against chronic lymphocytic leukemia cells [87]. Three-dimensional analysis of the grouping of fludarabine and DETA-NO· showed that at the optimum combination, cell death of 80–90% should be expected. As shown in Fig. 3, NO· also appears to preferentially sensitize cells that exhibit fludarabine resistance [87].

Conclusion and perspective

In this review, we have identified the underlying biological factors influencing the pro- and anti-metastatic effects of NO·. We discussed the various ways NO· can regulate tumor metastasis, ultimately providing justification for utilization of NO·-NSAIDs against carcinomas due to their ability to hinder cell-to-cell attachment and invasion. Several important aspects of NO· must be considered when assessing the biological outcome of NO· on cancer, such as the duration of NO· exposure, tumor microenvironment that NO· encounters, as well as specific signaling pathways that NO· regulates including MMP, integrin, cGMP-dependent, and COX-2 pathways. The double-edged nature of NO· action facilitates utilization of NO·-NSAIDs against carcinomas. Multiple factors including NO· pathways, tumor redox microenvironments, and NO·-mediated signaling cascades, must be considered in vitro and in vivo for potential therapies. Thus, NO·-NSAIDs can be important drugs for anti-cancer treatment if the effect of NO·-NSAIDs is optimized. Although NO· can assist in cancer progression by inducing angiogenesis and cell invasion, we conclude that nitric oxide-donating pro-drugs, such as NO·-NSAIDs, are a promising development for further research.

Conflict of interest

None declared.

Acknowledgements

References

[1] I.J. Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, Nat. Rev. Cancer 3 (6) (2003) 453–458.

[2] P. Mehlen, A. Puisieux, Metastasis: a question of life or death, Nat. Rev. Cancer 6 (6) (2006) 449–458.

[3] P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nat. Med. 12 (8) (2006) 895–904.

[4] J.A. Coulter, H.O. McCarthy, J. Xiang, W. Roedl, E. Wagner, T. Robson, D.G. Hirst, Nitric oxide–a novel therapeutic for cancer, Nitric Oxide 19 (2) (2008) 192–198.

[5] D.A. Wink, Y. Vodovotz, J. Laval, F. Laval, M.W. Dewhirst, J.B. Mitchell, The multifaceted roles of nitric oxide in cancer, Carcinogenesis 19 (5) (1998) 711–721.

[6] E.L. Williams, M.B. Djamgoz, Nitric oxide and metastatic cell behaviour, BioEssays 27 (12) (2005) 1228–1238.

[7] Z. Dong, A.H. Staroselsky, X. Qi, K. Xie, I.J. Fidler, Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells, Cancer Res. 54 (3) (1994) 789–793.

[8] K. Xie, S. Huang, Z. Dong, S.H. Juang, M. Gutman, Q.W. Xie, C. Nathan, I.J. Fidler, Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells, J. Exp. Med. 181 (4) (1995) 1333–1343.

[9] K. Xie, Z. Dong, I.J. Fidler, Activation of nitric oxide synthase gene for inhibition of cancer metastasis, J. Leukoc. Biol. 59 (6) (1996) 797–803.

[10] G.M. Tozer, V.E. Prise, D.J. Chaplin, Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine, Cancer Res. 57 (5) (1997) 948–955.

[11] E. Felley-Bosco, Role of nitric oxide in genotoxicity: implication for carcinogenesis, Cancer Metastasis Rev. 17 (1) (1998) 25–37.

[12] R.J. Bing, M. Miyataka, K.A. Rich, N. Hanson, X. Wang, H.D. Slosser, S.R. Shi, Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer, Clin. Cancer Res. 7 (11) (2001) 3385–3392.

[13] T. Ishikawa, N. Yoshida, H. Higashihara, M. Inoue, K. Uchiyama, T. Takagi, O. Handa, S. Kokura, Y. Naito, T. Okanoue, et al., Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice, Clin. Exp. Metastasis 20 (5) (2003) 445–450.

[14] X. Le, D. Wei, S. Huang, J.R. Lancaster Jr., Xie K: Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors, Proc. Natl. Acad. Sci. USA 102 (24) (2005) 8758–8763.

[15] S. Mocellin, Nitric oxide: cancer target or anticancer agent?, Curr Cancer Drug Targets 9 (2) (2009) 214–236.

[16] S. Moncada, E.A. Higgs, The discovery of nitric oxide and its role in vascular biology, Br. J. Pharmacol. 147 (Suppl 1) (2006) S193–S201.

[17] D.R. Riddell, J.S. Owen, Nitric oxide and platelet aggregation, Vitam. Horm. 57 (1999) 25–48.

[18] D.A. Wink, H.B. Hines, R.Y. Cheng, C.H. Switzer, W. Flores-Santana, M.P. Vitek, L.A. Ridnour, C.A. Colton, Nitric oxide and redox mechanisms in the immune response, J. Leukoc. Biol. 89 (6) (2011) 873–891.

[19] D. Fukumura, S. Kashiwagi, R.K. Jain, The role of nitric oxide in tumour progression, Nat. Rev. Cancer 6 (7) (2006) 521–534.

[20] D.G. DeNardo, M. Johansson, L.M. Coussens, Immune cells as mediators of solid tumor metastasis, Cancer Metastasis Rev. 27 (1) (2008) 11–18.

[21] T. Tsuruo, N. Fujita, Platelet aggregation in the formation of tumor metastasis, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 84 (6) (2008) 189–198.

[22] U. Forstermann, H.H. Schmidt, J.S. Pollock, H. Sheng, J.A. Mitchell, T.D. Warner, M. Nakane, F. Murad, Isoforms of nitric oxide synthase. Characterization and purification from different cell types, Biochem. Pharmacol. 42 (10) (1991) 1849–1857.

[23] M.W. Radomski, D.C. Jenkins, L. Holmes, S. Moncada, Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets, Cancer Res. 51 (22) (1991) 6073–6078.

[24] K. Zafirellis, A. Zachaki, G. Agrogiannis, K. Gravani, Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer, APMIS 118 (2) (2010) 115–124.

[25] X.J. Niu, Z.R. Wang, S.L. Wu, Z.M. Geng, Y.F. Zhang, X.L. Qing, Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue, World J. Gastroenterol. 10 (5) (2004) 725–728.

[26] M. Lahiri, J.H. Martin, Nitric oxide decreases motility and increases adhesion in human breast cancer cells, Oncol. Rep. 21 (2) (2009) 275–281.

[27] S.H. Juang, K. Xie, L. Xu, Y. Wang, J. Yoneda, I.J. Fidler, Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma, Cancer Biother. Radiopharm. 12 (3) (1997) 167–175.

[28] B. Wang, D. Wei, V.E. Crum, E.L. Richardson, H.H. Xiong, Y. Luo, S. Huang, J.L. Abbruzzese, K. Xie, A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis, Oncogene 22 (12) (2003) 1771–1782.

[29] K. Xie, S. Huang, Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency, Free Radic. Biol. Med. 34 (8) (2003) 969–986.

[30] J. Worthington, H.O. McCarthy, E. Barrett, C. Adams, T. Robson, D.G. Hirst, Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment, J. Gene Med. 6 (6) (2004) 673–680.

[31] R.T. Tell, R.J. Sydiskis, R.D. Isaacs, W.M. Davidson, Long-term cytotoxicity of orthodontic direct-bonding adhesives, Am. J. Orthod. Dentofacial. Orthop. 93 (5) (1988) 419–422.

[32] S. Califice, V. Castronovo, F. Van Den Brule, Galectin-3 and cancer (Review), Int. J. Oncol. 25 (4) (2004) 983–992.

[33] B.K. Moon, Y.J. Lee, P. Battle, J.M. Jessup, A. Raz, H.R. Kim, Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis, Am. J. Pathol. 159 (3) (2001) 1055–1060.

[34] Y.K. Song, T.R. Billiar, Y.J. Lee, Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide, Am. J. Pathol. 160 (3) (2002) 1069–1075.

[35] M.M. Sayed-Ahmad, M.A. Mohamad, Contribution of nitric oxide and epidermal growth factor receptor in anti-metastatic potential of paclitaxel in human liver cancer cell (HebG2), J. Egypt Natl. Canc. Inst. 17 (1) (2005) 35–41.

[36] P. Ferrer, M. Asensi, S. Priego, M. Benlloch, S. Mena, A. Ortega, E. Obrador, J.M. Esteve, J.M. Estrela, Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma, J. Biol. Chem. 282 (5) (2007) 2880–2890.

[37] J. Muntane, A.J. De la Rosa, L.M. Marin, F.J. Padillo, Nitric oxide and cell death in liver cancer cells, Mitochondrion 13 (3) (2013) 257–262.

[38] S. Fulda, Apoptosis pathways and their therapeutic exploitation in pancreatic cancer, J. Cell Mol. Med. 13 (7) (2009) 1221–1227.

[39] S. Ghavami, M. Hashemi, S.R. Ande, B. Yeganeh, W. Xiao, M. Eshraghi, C.J. Bus, K. Kadkhoda, E. Wiechec, A.J. Halayko, et al., Apoptosis and cancer: mutations within caspase genes, J. Med. Genet. 46 (8) (2009) 497–510.

[40] L.A. Ridnour, D.D. Thomas, C. Switzer, W. Flores-Santana, J.S. Isenberg, S. Ambs, D.D. Roberts, D.A. Wink, Molecular mechanisms for discrete nitric oxide levels in cancer, Nitric Oxide 19 (2) (2008) 73–76.

[41] A.F. Chambers, I.C. MacDonald, E.E. Schmidt, S. Koop, V.L. Morris, R. Khokha, A.C. Groom, Steps in tumor metastasis: new concepts from intravital videomicroscopy, Cancer Metastasis Rev. 14 (4) (1995) 279–301.

[42] H. Ponta, J. Sleeman, P. Herrlich, Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties, Biochim. Biophys. Acta 1198 (1) (1994) 1–10.

[43] H.I. Pass, Biology of metastatic disease, Semin. Thorac. Cardiovasc. Surg. 14 (1) (2002) 10–17.

[44] T. Shiomi, Y. Okada, MT1-MMP and MMP-7 in invasion and metastasis of human cancers, Cancer Metastasis Rev. 22 (2–3) (2003) 145–152.

[45] R. Poincloux, F. Lizarraga, P. Chavrier, Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia, J. Cell Sci. 122 (Pt 17) (2009) 3015–3024.

[46] S.K. Gupta, N.E. Vlahakis, Integrin alpha9beta1 mediates enhanced cell migration through nitric oxide synthase activity regulated by Src tyrosine kinase, J. Cell Sci. 122 (Pt 12) (2009) 2043–2054.

[47] Y. St-Pierre, J. Couillard, C. Van Themsche, Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases, Expert Opin. Ther. Targets 8 (5) (2004) 473–489.

[48] E.W. Thompson, M. Yu, J. Bueno, L. Jin, S.N. Maiti, F.L. Palao-Marco, H. Pulyaeva, J.W. Tamborlane, R. Tirgari, I. Wapnir, et al., Collagen induced MMP-2 activation in human breast cancer, Breast Cancer Res. Treat. 31 (2–3) (1994) 357–370.

[49] Y. Ishii, T. Ogura, M. Tatemichi, H. Fujisawa, F. Otsuka, H. Esumi, Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines, Int. J. Cancer 103 (2) (2003) 161–168.

[50] C. Jespersen, A. Doller, S. Akool el, M. Bachmann, R. Muller, P. Gutwein, H. Muhl, J. Pfeilschifter, W. Eberhardt, Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells, J. Cell. Physiol. 219 (2) (2009) 276–287.

[51] Y. Sun, J. Liu, F. Qian, Q. Xu, Nitric oxide inhibits T cell adhesion and migration by down-regulation of beta1-integrin expression in immunologically liver-injured mice, Int. Immunopharmacol. 6 (4) (2006) 616–626.

[52] W. Roberts, R. Riba, S. Homer-Vanniasinkam, R.W. Farndale, K.M. Naseem, Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen, J. Thromb. Haemost. 6 (12) (2008) 2175–2185.

[53] N. Conran, A. Gambero, H.H. Ferreira, E. Antunes, G. de Nucci, Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface, Biochem. Pharmacol. 66 (1) (2003) 43–50.

[54] K. Yudoh, H. Matsui, H. Tsuji, Nitric oxide induced by tumor cells activates tumor cell adhesion to endothelial cells and permeability of the endothelium in vitro, Clin. Exp. Metastasis 15 (6) (1997) 557–567.

[55] J. Folkman, Role of angiogenesis in tumor growth and metastasis, Semin. Oncol. 29 (6 Suppl 16) (2002) 15–18.

[56] M.H. Sun, X.C. Han, M.K. Jia, W.D. Jiang, M. Wang, H. Zhang, G. Han, Y. Jiang, Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma, World J. Gastroenterol. 11 (38) (2005) 5931–5937.

[57] O. Gallo, E. Masini, L. Morbidelli, A. Franchi, I. Fini-Storchi, W.A. Vergari, M. Ziche, Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer, J. Natl Cancer Inst. 90 (8) (1998) 587–596.

[58] T. Jiang, J.T. Yu, X.C. Zhu, Q.Q. Zhang, M.S. Tan, L. Cao, H.F. Wang, J. Lu, Q. Gao, Y.D. Zhang, et al., Angiotensin-(1–7) induces cerebral ischemic tolerance by

[59] Y.S. Choi, H.J. Choi, J.K. Min, B.J. Pyun, Y.S. Maeng, H. Park, J. Kim, Y.M. Kim, Y.G. Kwon, Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production, Blood 114 (14) (2009) 3117–3126.

[60] G.K. Kolluru, S. Sinha, S. Majumder, A. Muley, J.H. Siamwala, R. Gupta, S. Chatterjee, Shear stress promotes nitric oxide production in endothelial cells by sub-cellular delocalization of eNOS: a basis for shear stress mediated angiogenesis, Nitric Oxide 22 (4) (2010) 304–315.

[61] X. Bessa, J.I. Elizalde, F. Mitjans, V. Pinol, R. Miquel, J. Panes, J. Piulats, J.M. Pique, A. Castells, Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1, Gastroenterology 122 (4) (2002) 1122–1132.

[62] M. Spiecker, H. Darius, K. Kaboth, F. Hubner, J.K. Liao, Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants, J. Leukoc. Biol. 63 (6) (1998) 732–739.

[63] H. Huang, A. Lavoie-Lamoureux, K. Moran, J.P. Lavoie, IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells, Am. J. Physiol. Lung Cell. Mol. Physiol. 292 (5) (2007) L1147–L1154.

[64] Y. Cao, Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis, Nat. Rev. Cancer 5 (9) (2005) 735–743.

[65] T. Karpanen, M. Egeblad, M.J. Karkkainen, H. Kubo, S. Yla-Herttuala, M. Jaattela, K. Alitalo, Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth, Cancer Res. 61 (5) (2001) 1786–1790.

[66] H. Yasuoka, M. Tsujimoto, K. Yoshidome, M. Nakahara, R. Kodama, T. Sanke, Y. Nakamura, Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis, BMC Cancer 8 (2008) 340.

[67] Y. Nakamura, H. Yasuoka, M. Tsujimoto, K. Yoshidome, M. Nakahara, K. Nakao, M. Nakamura, K. Kakudo, Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis, Clin. Cancer Res. 12 (4) (2006) 1201–1207.

[68] J.H. Baek, J.E. Jang, C.M. Kang, H.Y. Chung, N.D. Kim, K.W. Kim, Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis, Oncogene 19 (40) (2000) 4621–4631.

[69] J.E. Park, H.S. Tan, A. Datta, R.C. Lai, H. Zhang, W. Meng, S.K. Lim, S.K. Sze, Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes, Mol. Cell. Proteomics 9 (6) (2010) 1085–1099.

[70] L.M. Postovit, M.A. Adams, G.E. Lash, J.P. Heaton, C.H. Graham, Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis, Int. J. Cancer 108 (1) (2004) 47–53.

[71] L.E. Huang, W.G. Willmore, J. Gu, M.A. Goldberg, H.F. Bunn, Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling, J. Biol. Chem. 274 (13) (1999) 9038–9044.

[72] K.B. Sandau, J. Zhou, T. Kietzmann, B. Brune, Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide, J. Biol. Chem. 276 (43) (2001) 39805–39811.

[73] D.R. Siemens, J.P. Heaton, M. Adams, J. Kawakami, C.H. Graham, Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer, Urology 74 (4) (2009) 878–883.

[74] C.N. Chen, F.J. Hsieh, Y.M. Cheng, K.J. Chang, P.H. Lee, Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer, J. Surg. Oncol. 94 (3) (2006) 226–233.

[75] A. Tyryshkin, F.M. Gorgun, E. Abdel Fattah, T. Mazumdar, L. Pandit, S. Zeng, Eissa NT: Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells, J. Biol. Chem. 285 (1) (2010) 784–792.

[76] A.J. Burke, F.J. Sullivan, F.J. Giles, S.A. Glynn, The yin and yang of nitric oxide in cancer progression, Carcinogenesis 34 (3) (2013) 503–512.

[77] J.L. Burgaud, E. Ongini, P. Del Soldato, Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents, Ann. N. Y. Acad. Sci. 962 (2002) 360–371.

[78] C. Stolfi, V. De Simone, F. Pallone, G. Monteleone, Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer, Int. J. Mol. Sci. 14 (9) (2013) 17972–17985.

[79] V. Vaish, H. Piplani, C. Rana, K. Vaiphei, S.N. Sanyal, NSAIDs may regulate EGR-1-mediated induction of reactive oxygen species and non-steroidal anti-inflammatory drug-induced gene (NAG)-1 to initiate intrinsic pathway of apoptosis for the chemoprevention of colorectal cancer, Mol. Cell. Biochem. 378 (1–2) (2013) 47–64.

[80] E. Domingo, D.N. Church, O. Sieber, R. Ramamoorthy, Y. Yanagisawa, E. Johnstone, B. Davidson, D.J. Kerr, I.P.M. Tomlinson, R. Midgley, Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer, J. Clin. Oncol. 31 (34) (2013) U4234–U4297.

[81] H. Cheng, M.Y. Mollica, S.H. Lee, L. Wang, C.A. Velazquez-Martinez, S. Wu, Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-

NSAIDs) on melanoma cell adhesion, Toxicol. Appl. Pharmacol. 264 (2) (2012) 161–166.

[82] J.L. Williams, S. Borgo, I. Hasan, E. Castillo, F. Traganos, B. Rigas, Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention, Cancer Res. 61 (8) (2001) 3285–3289.

[83] K. Kashfi, Y. Ryann, L.L. Qiao, J.L. Williams, J. Chen, P. Del Soldato, F. Traganos, B. Rigas, Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect, J. Pharm. Exp. Ther. 303 (3) (2002) 1273–1282.

[84] S.Y. Olson, H.J. Garban, Regulation of apoptosis-related genes by nitric oxide in cancer, Nitric Oxide 19 (2) (2008) 170–176.

[85] X. Pan, X. Wang, W. Lei, L. Min, Y. Yang, X. Wang, J. Song, Nitric oxide suppresses transforming growth factor-beta1-induced epithelial-to-mesenchymal transition and apoptosis in mouse hepatocytes, Hepatology 50 (5) (2009) 1577–1587.

[86] B. Brune, Nitric oxide: NO apoptosis or turning it ON?, Cell Death Differ 10 (8) (2003) 864–869.

[87] D.J. Adams, M.C. Levesque, J.B. Weinberg, K.L. Smith, J.L. Flowers, J. Moore, O.M. Colvin, R. Silber, Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes, Leukemia 15 (12) (2001) 1852–1859.